Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 16, 2019

View Archived Issues

Testosterone replacement cells a step closer

For antioxidants, bad news is worse than good news is good

Weak albumin-binding PSMA radioligands for improved prostate cancer therapy

New anti-CD30 ADC shows promising preclinical profile for CD30-positive hematological malignancies

First clinical trial of an extracellular matrix hydrogel in post-myocardial infarction patients

Researchers present YU-253911, a new oxopyrazole antibiotic against Acinetobacter

Competition between HuR and miR-330 modulates STAT3 expression promoting muscle wasting in cachexia

New GAPDH transgenic mouse model mimicking angioimmunoblastic T-cell lymphoma

Cyteir Therapeutics secures funding and doses first patient in phase I/II study of CYT-851

Topline results reported from phase II study of REL-1017 in treatment-resistant depression

Diamyd Medical enters agreement for phase II study of diabetes vaccine candidate

Yumanity Therapeutics discloses SCD1/SCD5 inhibitors

Kappa-opioid receptor antagonists presented by the University of Kansas, University of Florida

Medipol University discovers hexokinase-2 inhibitors

Surprise discovery may improve malaria vaccine strategy

New eukaryotic translation initiation factor 2B activators patented by Denali Therapeutics

Pfizer identifies muscarinic acetylcholine M4 receptor agonists

[212Pb]Rituximab treatment to overcome hematological toxicity in non-Hodgkin's lymphoma

Novavax begins pivotal trial of NanoFlu in older adults

Principia Biopharma reports preliminary data from phase I/II trial of PRN-1008 in ITP

Aura updates data from phase Ib/II study of AU-011 in primary choroidal melanoma

Sanofi begins phase I/II study of SAR-439483 in LCA caused by GUCY2D mutations

Radiolabeled anti-CD37 monoclonal antibody shows promise in preclinical lymphoma, CLL studies

AL-S Pharma initiates phase I study of AP-101 in ALS

Phase III SEQUOIA study of pegilodecakin in metastatic pancreatic cancer misses primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 9, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...